To access the full text documents, please follow this link: http://hdl.handle.net/2445/111156

Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation
Torres, Berta; Guardo, Alberto C.; Leal, Lorna; León García, Agathe; Lucero, Constanza; Álvarez Martínez, Míriam; Martínez Yoldi, Miguel Julián; Vila Estapé, Jordi; Martínez Rebollar, María; González Cordón, Ana; Gatell, José M.; Plana Prades, Montserrat; García Alcaide, Felipe
Introduction Monotherapy with protease-inhibitors (MPI) may be an alternative to cART for HIV treatment. We assessed the impact of this strategy on immune activation, bacterial translocation and inflammation. Methods We performed a cross-sectional study comparing patients on successful MPI (n=40) with patients on cART (n=20). Activation, senescence, exhaustion and differentiation stage in CD4+ and CD8+ T lymphocyte subsets, markers of monocyte activation, microbial translocation, inflammation, coagulation and low-level viremia were assessed. Results CD4+ or CD8+ T lymphocyte subset parameters were not significantly different between both groups. Conversely, as compared with triple cART, MPI patients showed a higher proportion of activated monocytes (CD14+ CD16−CD163+ cells, p=0.031), soluble markers of monocyte activation (sCD14 p=0.004, sCD163 p=0.002), microbial translocation (lipopolysaccharide (LPS)-binding protein; LBP p=0.07), inflammation (IL-6 p=0.04) and low-level viremia (p=0.035). In a multivariate model, a higher level of CD14+ CD16−CD163+ cells and sCD14, and presence of very low-level viremia were independently associated with MPI. Monocyte activation was independently associated with markers of inflammation (IL-6, p=0.006), microbial translocation (LBP, p=0.01) and low-level viremia (p=0.01). Conclusions Patients on MPI showed a higher level of monocyte activation than patients on standard therapy. Microbial translocation and low-level viremia were associated with the high level of monocyte activation observed in patients on MPI. The long-term clinical consequences of these findings should be assessed.
-VIH (Virus)
-Antiretrovirals
-Limfòcits
-Translocació (Genètica)
-Inhibidors enzimàtics
-HIV (Viruses)
-Antiretroviral agents
-Lymphocytes
-Translocation (Genetics)
-Enzyme inhibitors
cc-by (c) Torres, Berta et al., 2014
http://creativecommons.org/licenses/by/3.0/es
Article
Article - Published version
BioMed Central
         

Show full item record

Related documents

Other documents of the same author

Torres, Berta; Guardo, Alberto C.; Leal, Lorna; Leon, Agathe; Lucero, Constanza; Álvarez Martínez, Míriam; Martínez Yoldi, Miguel Julián; Vila Estapé, Jordi; Martinez-Rebollar, M.; González-Cordón, Ana; Gatell, José M.; Plana, Montserrat; García Alcaide, Felipe
Torres, Berta; Rallón, Norma I.; Loncá, Montserrat; Díaz Lorca, Maria Alba; Alós i Hernández, Llúcia; Martínez Chamorro, Esteban José; Cruceta, Anna; Arnaiz Gargallo, Juan Alberto; Leal, Lorna; Lucero, Constanza; León, Agathe; Sánchez, Marcelo; Negredo, Eugenia; Clotet i Sala, Bonaventura; Gatell, José M.; Benito, José M.; García Alcaide, Felipe
Torres, Berta; Rallón, Norma I.; Loncá, Montserrat; Díaz Lorca, Maria Alba; Alós i Hernández, Llúcia; Martínez Chamorro, Esteban José; Cruceta, Anna; Arnaiz Gargallo, Juan Alberto; Leal, Lorna; Lucero, Constanza; León, Agathe; Sánchez, Marcelo; Negredo, Eugenia; Clotet i Sala, Bonaventura; Gatell, José M.; Benito, José M.; García Alcaide, Felipe
Egaña Gorroño, Lander; Escribà, Tuixent; Boulanger, Nicolas; Crespo Guardo, Alberto; León García, Agathe; Bargalló, Manel Enric; García, Felipe; Gatell, José M.; Plana Prades, Montserrat; Arnedo, Mireia
Crespo Guardo, Alberto; Álvarez Fernández, Carmen; Arberas, Hodei; García-Pérez, Javier; García Alcaide, Felipe; Bargalló, Manuel Enric; Maleno, María José; Gatell, José M.; Mothe, Beatriz; Alcamí, José; Sánchez-Palomino, Sonsoles; Plana Prades, Montserrat
 

Coordination

 

Supporters